Price Over Earnings Overview: Pfizer - Pfizer ( NYSE:PFE )
Looking into the current session, Pfizer Inc. PFE shares are trading at $25.84, after a 0.39% increase. Moreover, over the past month, the stock spiked by 4.24%, but in the past year, fell by 10.65%.
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
Pfizer Inc. ( PFE ) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
My 5 Favorite Stocks to Buy Right Now
Not every ticker worth owning at this time has raced to an uncomfortably high price.
Why Is Achieve Life Sciences Stock Skyrocketing Thursday? - Achieve Life Sciences ( NASDAQ:ACHV )
FDA submission backed by two Phase 3 trials showing higher abstinence rates. HC Wainwright sets $12 target, citing an undervalued stock and $13 billion market. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here → Achieve Life Sciences Inc.
This Is What Whales Are Betting On Pfizer - Pfizer ( NYSE:PFE )
High-rolling investors have positioned themselves bullish on Pfizer PFE, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Why Is Gilead Sciences Stock Falling Thursday? - CVS Health ( NYSE:CVS ) , Gilead Sciences ( NASDAQ:GILD )
CVS rejects Gilead's $28K-a-year HIV prevention drug Yeztugo from coverage. The federal judge ordered CVS Caremark to pay nearly $290 million in Medicare fraud cases. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. CVS Health Inc.
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - Ascentage Pharma Group ( NASDAQ:AAPG )
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million ( RMB217.4 million ) , primarily attributable to the expansion of NRDL coverage
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
ROCKVILLE, Md. and SUZHOU, China, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International ( Ascentage Pharma ) ( NASDAQ: AAPG. HKEX: 6855 ) ( referred hereinto as "Ascentage Pharma," the "Company," "we," "us" or "our" ) , a global, commercial stage, integrated biopharmaceutical ...
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
My Top Dividend-Paying, Deep-Value Stock to Buy in August
You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock.
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Eli Lilly ( NYSE:LLY )
Novo's pill requires ~75 times more active ingredient per week than Wegovy injections. Lilly has $808.5 million in orforglipron inventory ahead of its planned 2026 launch. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Alation Unveils "Alation Chat with Your Data" to Help Business Teams Move From Searching to Solving
REDWOOD CITY, Calif., Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Alation Inc., the data intelligence company, today introduced Alation Chat with Your Data, enabling anyone in the enterprise to get fast, accurate answers from structured data-just by asking questions in plain English.
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - Inhibikase Therapeutics ( NASDAQ:IKT )
BOSTON and ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc.
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Pfizer's yield is high, and so too is its payout ratio.
Basilea on track with strong 2025 half-year results
Ad hoc announcement pursuant to Art. 53 LR ...
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis ( FAP )
August ...
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year
These three businesses have been raising their payouts for at least 16 consecutive years.
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain ( France ) , August 18, 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years ...
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain ( France ) , August 18, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus ...
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma ( NASDAQ: AAPG. HKEX: 6855 ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet ...
2 Top Dividend Stocks to Buy on the Dip
These blue chip healthcare stocks could still deliver strong long-term returns.
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE )
Inclacumab fails to reduce VOC rates in sickle cell patients in Phase 3 trial. Pfizer will continue developing its broader sickle cell portfolio. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing. Pfizer Inc.
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Pfizer beat expectations last quarter and it raised its guidance.
Celcuity ( CELC ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 14, 2025 at 4:30 p.m. ETChief Executive Officer and Cofounder - Brian SullivanContinue reading ...
Celcuity Expenses Jump 81 Percent
Celcuity ( NASDAQ:CELC ) , a clinical-stage biotechnology company developing targeted therapies for cancer, released its second quarter 2025 earnings on August 14, 2025. The highlight was topline Phase 3 data for lead drug gedatolisib, which showed unprecedented results in advanced breast cancer ...
Brandon Hall Group™ Announces 2025 HCM Excellence Awards® Winners in Live Broadcast
Boca Raton, FL, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Brandon Hall Group™, the leading HCM research and analyst firm, today announced the winners of its 2025 HCM Excellence Awards® during a special live broadcast.
How Do Investors Really Feel About Pfizer? - Pfizer ( NYSE:PFE )
Pfizer's PFE short percent of float has risen 8.57% since its last report. The company recently reported that it has 107.78 million shares sold short, which is 1.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.69 days to cover their ...
Traws Pharma Posts Q2 Revenue Jump
Traws Pharma ( NASDAQ:TRAW ) , a clinical-stage biopharmaceutical company focused on antivirals for COVID-19 and influenza, released its second quarter results on August 14, 2025. The most notable news was a sudden jump in reported revenue, up to $2.7 million ( GAAP ) from $0.06 million ( GAAP ) ...
Protalix Revenue Jumps 16 Percent in Q2
Protalix BioTherapeutics ( NYSEMKT:PLX ) , a biopharmaceutical company specializing in plant cell-based protein production, announced its second quarter results on August 14, 2025. Revenues from product sales grew 16% to $15.4 million compared to Q2 2024.
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - Traws Pharma ( NASDAQ:TRAW )
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ( ratutrelvir ) and influenza ( Tivoxavir marboxil, TXM )
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ( ratutrelvir ) and influenza ...
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( NASDAQ: LVTX, "LAVA," or the "Company" ) , a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced ...
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart ( OTC:VXRT ) , a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a revenue surge to $39.7 million ( GAAP ) -well above the $2.03 million analyst consensus-driven by a ...
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.
XOMA Revenue Jumps 39% in Fiscal Q2
XOMA ( NASDAQ:XOMA ) , a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company's revenue ( GAAP ) reached $13.1 million for Q2 2025, surpassing analyst GAAP estimates of $9.39 million.
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive.
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
CDC shooter's writings revealed anti-vaccine beliefs and distrust of COVID-19 shots. The NIH chief says that mRNA vaccines lack viability due to public distrust. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → A group of former U.S.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
What's Going On With Merck Stock Tuesday? - Merck & Co ( NYSE:MRK ) , Pfizer ( NYSE:PFE )
The Keytruda-Padcev combo improved event-free and overall survival in the Phase 3 trial. No new safety issues were found; Merck will present the results at the medical meeting. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → On Tuesday, Merck & Co. Inc.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
